Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study

Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response

(2018) Felipe V. Pereira et al.   Oncotarget

Metformin and stage IV colorectal cancer in elderly.

(2018) Rohit Bishnoi et al.   JOURNAL OF CLINICAL ONCOLOGY

Metformin use and survival of lung cancer patients: Meta-analysis findings

(2017) J Zhao et al.   INDIAN JOURNAL OF CANCER

Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma

(2017) Jie-Jen Lee et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis

(2017) Fanqiang Meng et al.   Journal of Diabetes Research

Metformin use and survival of lung cancer patients: Meta-analysis findings

(2017) J Zhao et al.   INDIAN JOURNAL OF CANCER

How generalizable are the SEER registries to the cancer populations of the USA?

(2016) Tzy-Mey Kuo et al.   CANCER CAUSES & CONTROL

NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis

(2016) Hui Wang et al.   Science Translational Medicine

DPPIV/CD26: a tumor suppressor or a marker of malignancy?

(2016) Aline Beckenkamp et al.   TUMOR BIOLOGY

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

(2015) Rosa Barreira da Silva et al.   NATURE IMMUNOLOGY

Dipeptidyl-Peptidase IV Activity Is Correlated with Colorectal Cancer Prognosis

(2015) Gorka Larrinaga et al.   PLoS One

Survival Benefits of Metformin for Colorectal Cancer Patients with Diabetes: A Systematic Review and Meta-Analysis

(2014) Zu-Bing Mei et al.   PLoS One

The role of CD26/dipeptidyl peptidase IV in cancer

(2007) Pamela et al.   Frontiers in Bioscience-Landmark